Skip to content
Buy This GLP
← Research
Safety

Compounded Semaglutide and Liraglutide Impurities: A Manufacturer's Lab Study

Researchers affiliated with Novo Nordisk found differences in impurities and peptide presentation in laboratory tests of selected products.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read
What this study measured, and what it did notamino acid deletions and additionsfoundunidentified impuritiesfoundchanges in strength after lightfoundreduced physical stabilityfoundan immune reaction in a patientnot measuredConducted entirely by employees of the originator's manufacturer.

The researchers compared samples of follow-on and compounded products with the originator semaglutide and liraglutide products. Our review of funding in GLP-1 studies explains how to read disclosures alongside study methods. This comparison was conducted by researchers affiliated with the originator manufacturer.

Who did the work

Nine authors disclosed that they were employees and shareholders of Novo Nordisk, the manufacturer of the originator products. The tenth disclosed that he was a shareholder and worked at Novo Nordisk when the study was conducted[1].

What they found

Follow-on drug substance, follow-on products and compounded products all showed impurity profiles distinct from the originators: amino acid deletions and additions, and impurities the analysis could not identify. A patient can verify the dispensing pharmacy before filling a prescription, though that check cannot establish what is in a specific vial.

Exposed to light, compounded semaglutide differed significantly from the originator on strength, total impurities and high-molecular-weight protein content. The liraglutide follow-ons had reduced physical stability.

What to ask the dispensing pharmacy

Ask the pharmacy how to store your prescription and what to do if a shipment arrives outside the stated storage conditions. The guide to compounded semaglutide safety describes evidence on dispensing and labeling. The laboratory study examined specific samples and does not establish how every compounded product behaves.

Ask the pharmacist to show you how to measure your prescribed dose. The guide to vial dosing errors explains why concentration and syringe markings matter. Dosing errors are a separate issue from the impurities measured in this study.

Frequently asked

Are compounded GLP-1 products dangerous?
This study did not test that. It found different impurity profiles and greater immunogenic potential in a laboratory assay, with no patients involved and no clinical outcome measured.
Who ran the study?
All ten authors reported holding Novo Nordisk shares. Nine were employees and the tenth had worked there when the study was conducted.
What does 'immunogenic potential' mean?
Impurities were used to stimulate immune cells grown from healthy donors, and more and different peptides were displayed than with the originators. The assay shows peptide presentation in the lab. It does not estimate how often patients have an immune reaction.
What is the most practical finding?
The tested compounded semaglutide samples differed from the reference product after light exposure. Ask your dispensing pharmacy which storage instructions apply to your prescription.

Sources

  1. [1] Kopp KL, et al. (2026). Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists Pharmaceutical Research. PMID 42533250

More in Safety